Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Open accessThe DOI matches its Crossref record; 203 of the 203 references it cites were found in a registry or an index.
Abstract
The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other’s work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general, European and US guidelines recommend more-restrictive criteria for resection than Asian guidelines7,22–27.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [23]
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,700
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Cited by
Items 101–200 of 678
You, R., Xu, Q., Wang, Q., Zhang, Q., Zhou, W.-Z., Cao, C., Huang, X., Ji, H., Lv, P.-H., Jiang, H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.816198 · Cited by 25
“These patients were classified as TACE refractory and not TACE refractory according to the criteria submitted by the Japan Society of Hepatology (18).”
MethodHuang, P., Zhou, C., Wu, F., Xiao, Y., Qian, X., Wang, Y., Yang, C., & Zeng, M. (2022) · European Radiology · doi:10.1007/s00330-022-09282-5 · Cited by 28
“dence of portal vein tumor thrombus and intrahepatic metastasis [2, 3].”
BackgroundCurrent status and prospect of treatments for recurrent hepatocellular carcinoma
Yang, Y.-Q., Wen, Z.-Y., Liu, X., Ma, Z.-H., Liu, Y.-E., Cao, X., Hou, L., & Xie, H. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i2.129 · Cited by 30
Hiraoka, A., Kumada, T., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13934 · Cited by 26
“Diagnosis of HCC was essentially performed according to the consensus statement of the Japan Society of Hepatology, 15 and based on an increasing course of alpha ‐ fetoprotein (AFP) as well as dynamic CT, 16 magnetic resonance imaging, 17,18 contrast ‐ enhanced ultrasonography with perflubutane, 19…”
MethodSelf-citationChen, S., Shi, F., Wu, Z., Wang, L., Cai, H., Ma, P., Zhou, Y.-M., Mai, Q., Wang, F., Tang, S., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s417550 · Cited by 29
“HBV 90 (90) 45 (90) 45 (90) HCV 6 (6) 2 (4) 4 (8)”
InfluentialProgression of hepatocellular carcinoma after radiofrequency ablation: Current status of research
Wu, S., Li, Z., Yao, C., Dong, S., Gao, J., Ke, S., Zhu, R., Huang, S., Wang, S., Xu, L., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1032746 · Cited by 27
“ablation (RFA) as first-line therapies (2, 3).”
Minami, Y., Nishida, N., & Kudo, M. (2022) · Liver Cancer · doi:10.1159/000528538 · Cited by 31
Self-citationCao, Y., Tang, H., Hu, B., Zhang, W., Wan, T., Han, J., Jiao, T., Li, J., Li, X., Yang, Z., et al. (2023) · HPB · doi:10.1016/j.hpb.2023.03.004 · Cited by 27
Gadoxetic Acid–Enhanced Liver MRI
Ichikawa, S., & Goshima, S. (2023) · Investigative Radiology · doi:10.1097/rli.0000000000000990 · Cited by 23
Tang, S., Shi, F., Xiao, Y., Cai, H., Ma, P., Zhou, Y.-M., Wu, Z., Chen, S., & Guo, W. (2025) · Hepatology International · doi:10.1007/s12072-024-10762-7 · Cited by 24
“This combination has thus been recommended by expert consensus for use in patients with PVTT but no extrahepatic spread [19].”
Zhang, W., Hou, S.-Z., Chen, Y., Mao, F., Dong, Y., Chen, J., & Wang, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.862297 · Cited by 26
Zhang, J.-X., Yan, H., Ye, D., Liu, J. H., Liu, S., Zu, Q., & Shi, H. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2081872 · Cited by 25
“In the current study, AFP level, Child-Pugh class, maximum tumour diameter, metastasis, and BCLC stage were demonstrated to predict OS in HCC patients treated with TACE, which were similar to previously reported data [26,27].”
ResultAlbarrak, J., & Al-Shamsi, H. O. (2023) · Cancers · doi:10.3390/cancers15072001 · Cited by 31
“Child-Pugh class B; and (iii) patients who are unlikely to respond to TACE (TACE-resistant tumor) [57,81].”
BackgroundMethodKudo, M. (2023) · Liver Cancer · doi:10.1159/000532023 · Cited by 24
“The concept of “ TACE refractory ” [27, 28] or “ TACE unsuitable ” [17, 18] was proposed in recent years, resulting in a gradual shift in treatment strategies that prioritize upfront systemic therapy followed by TACE over TACE alone for patients with good liver function and a high tumor burden who…”
BackgroundSelf-citationLocoregional therapies for hepatocellular carcinoma: The current status and future perspectives
Chen, J., Jin, Z., Zhong, B., Fan, W., Zhang, W., Luo, B., Wang, Y., Teng, G., & Zhu, H. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12554 · Cited by 25
“3,5,51 However, no RCThas yet demonstrated a clinical benefitfromHAIC in a Western population with HCC.”
BackgroundFujita, N., Kanogawa, N., Makishima, H., Ogasawara, S., Maruta, S., Iino, Y., Shiko, Y., Kanzaki, H., Koroki, K., Kobayashi, K., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13827 · Cited by 21
“The treatment policy for patients with early‐stage HCC in three institutions (Chiba University Hospital, Asahi General Hospital, and Kimitsu Chuo Hospital) followed Japanese standard practice.(7) Initially, we investigated whether surgical resection might be indicated.”
MethodSelf-citationUnome, S., Imai, K., Takai, K., Miwa, T., Hanai, T., Nishigaki, Y., Hayashi, H., Kochi, T., Shimizu, S., Nagano, J., et al. (2022) · Cancers · doi:10.3390/cancers14246089 · Cited by 24
Takaki, S., Kurosaki, M., Mori, N., Tsuji, K., Ochi, H., Marusawa, H., Nakamura, S., Tada, T., Narita, R., Uchida, Y., et al. (2023) · Investigational New Drugs · doi:10.1007/s10637-023-01349-4 · Cited by 21
“Cox regression analysis was conducted to determine AE related to OS or PFS [15].”
MethodSelf-citationFan, Z., Jin, M., Zhang, L., Wang, N., Li, M., Wang, C., Feng, W. Q., Zhang, P., Du, X., Sun, X., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-330461 · Cited by 25
“14 The differences in patient’s outcomes between type II/III and type I HCCs were no longer significant, those between type IV and the other three gross subtypes remained significant after IPTW adjustment.”
Furusawa, A., Naganuma, A., Suzuki, Y., Hoshino, T., Yasuoka, H., Tamura, Y., Naruse, H., Hatanaka, T., & Kakizaki, S. (2022) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-022-01605-9 · Cited by 21
“On the basis of the results of the IMbrave 150 trial, the combination of atezolizumab, a programmed cell death ligand 1 (PD-L1) antibody, as well as bevacizumab, a vascular endothelial growth factor (VEGF) antibody, represents a novel first-line therapy in patients with HCC [7, 8].”
BackgroundHoshino, T., Naganuma, A., Furusawa, A., Suzuki, Y., Hirai, K., Sakamoto, I., Ogawa, T., Ogawa, A., Hatanaka, T., & Kakizaki, S. (2022) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-022-01644-2 · Cited by 21
“1 3 bevacizumab represents a novel first-line therapy for HCC patients [5, 6], as it dramatically improved the prognosis of advanced HCC patients.”
Chen, Q., Lyu, N., Wang, X., Jiang, X., Yue, H., Chen, S., Zhong, S., Huang, Z.-L., Chen, M., & Zhao, M. D. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000683 · Cited by 22
“Hepatic arterial infusion chemotherapy (HAIC) is recommended in several Asian treatment guidelines as a fi rst-line treatment for localized advanced HCC [9,10] .”
BackgroundDiao, L., Wang, C., You, R., Leng, B., Yu, Z., Xu, Q., Cheng, Y., & Yin, G. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16463 · Cited by 19
“11,12 A considerable number of studies have attempted to investigate the ef fi cacy of locoregional treatment with HAIC for HCC when TACE is ineffective or unsuitable, 8,13 while the survival bene fi ts provided by a single HAIC treatment option are also limited and even inferior to those of…”
BackgroundHou, J., Berg, T., Vogel, A., Piratvisuth, T., Trojan, J., Toni, E. N. D., Kudo, M., Malinowsky, K., Findeisen, P., Hegel, J. K., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101263 · Cited by 24
Self-citationHiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., Tsuji, K., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14136 · Cited by 21
Self-citationSho, T., Suda, G., Yamamoto, Y., Furuya, K., Baba, M., Ogawa, K., Kubo, A., Tokuchi, Y., Fu, Q., Yang, Z., et al. (2022) · Cancers · doi:10.3390/cancers14163938 · Cited by 18
“Therefore, recent guidelines recommend the combination of atezolizumab and bevacizumab as a first-line systemic therapy for patients with unresectable HCC [8,9].”
BackgroundSu, T., Chang, S.-H., Chen, C., Liao, S., Tseng, T., Hsu, S., Hong, C., Liu, C., Yang, H., Liu, C., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13932 · Cited by 19
“A few serological markers have been proposed for HCC surveillance including alpha‐fetoprotein (AFP), prothrombin induced by vitamin K absence or antagonist‐II, and the Lens culinaris agglutinin‐reactive fraction of AFP (AFP‐L3).(3) Among them, serum AFP is the most widely used diagnostic marker for HCC.”
BackgroundCostentin, C. E., Audureau, É., Park, Y. N., Langella, S., Vibert, É., Laurent, A., Cauchy, F., Scatton, O., Chirica, M., Rhaiem, R., et al. (2023) · Liver International · doi:10.1111/liv.15683 · Cited by 17
Self-citationKudo, M. (2024) · Liver Cancer · doi:10.1159/000538558 · Cited by 18
“These results validate the consensus statements of the Asia-Paci fi c Primary Liver Cancer Expert Association and the Japan Society of Hepatology [12, 13].”
ResultSelf-citationMoriguchi, M., Kataoka, S., & Itoh, Y. (2024) · Cancers · doi:10.3390/cancers16132387 · Cited by 19
“…and reduction in tumor interstitial pressure, (2) inhibition of tumor progression by blocking VEGF system signals released after TACE, and (3) constriction of embolization range due to tumor size reduction from that prior to drug administration, thus possibly preserving liver function [77,78].”
BackgroundSelf-citationChen, S., Wang, X., Yuan, B., Peng, J., Zhang, Q., Yu, W., Ge, N., Weng, Z., Huang, J., Liu, W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52700-z · Cited by 18
“…without extrahepatic metastasis (portal vein invasion) are usually differentiated, and loco-regional therapies including HAIC were performed as treatment option for advanced HCC with portal invasion following the management guidelines of HCC 5,6,28 .”
Effects of Anatomical or Non-Anatomical Resection of Hepatocellular Carcinoma on Survival Outcome
Kwon, J. H., Lee, J. W., Lee, J. W., & Lee, Y. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051369 · Cited by 18
“The practice guidelines for HCC recommend resection as the treatment of choice for single or limited-numbered HCCs without significant cirrhosis or portal hypertension [3,4]; however, the guidelines are unclear about whether anatomical resection (AR) or non-anatomic resection (NAR) is superior.”
MethodZhang, X., Cai, H., Peng, W., Wang, H., Wu, J., Zhu, X., Weixin, G. U. O., Xie, F., Zhang, Y., Wang, M., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02498-z · Cited by 23
Zhang, J., Chen, Y.-X., Zhou, C., Liu, J., Liu, S., Shi, H., & Zu, Q. (2022) · Hepatology Research · doi:10.1111/hepr.13801 · Cited by 19
“Increasing evidence suggests that the administration of combination TKI therapy at an earlier time point is a feasible and effective strategy for these patients.(19,20) In patients who were refractory to TACE, our study showed a trend of longer median PFS and OS in the TACE‐lenvatinib group than in the TACE‐sorafenib…”
HS1BP3, transcriptionally regulated by ESR1, promotes hepatocellular carcinoma progression
Hu, X., Pan, H., Zhou, S., Pang, Q., Wang, Y., Zhu, C., Liu, H., Jin, H., & Xu, A. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.07.047 · Cited by 17
An overview: Management of patients with advanced hepatocellular carcinoma
Wang, J., Wu, R., Sun, J.-Y., Lei, F., Tan, H., & Lu, X. (2022) · BioScience Trends · doi:10.5582/bst.2022.01109 · Cited by 19
Asano, K., Kageyama, K., Yamamoto, A., Jogo, A., Uchida‐Kobayashi, S., Sohgawa, E., Murai, K., Kawada, N., & Miki, Y. (2023) · Liver Cancer · doi:10.1159/000530441 · Cited by 17
Kang, H., Lee, J. M., & Kim, S. W. (2023) · ULTRASONOGRAPHY · doi:10.14366/usg.23051 · Cited by 17
“CEUS with intravascular agents was included in the EASL and 2018 KLCA-NCC guidelines, as well as the CEUS LI-RADS, while CEUS with Kupffer agents was included in the APASL and JSH guidelines [4,6-8].”
MethodCurrent Therapeutic Strategies for Hepatocellular Carcinoma in Japan
Kudo, M. (2023) · Liver Cancer · doi:10.1159/000534304 · Cited by 21
Self-citationKai, M., Hikita, H., Kazuki, M., Tahata, Y., Shinkai, K., Doi, A., Ohkawa, K., Miyazaki, M., Ishida, H., Matsumoto, K., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0294590 · Cited by 17
Self-citationZhang, J.-X., Cheng, Y., Wei, J., Fan, W.-L., Liu, J., Zhou, C., Liu, S., Shi, H., Chu, X., Zheng, W., et al. (2024) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-024-03724-x · Cited by 20
“PVTT was graded according to the guidelines of the Japan Society of Hepatology [23], which included Vp1 (segmentary branch), Vp2 (secondary-order branch), Vp3 (first-order branch), and Vp4 (main portal vein trunk).”
Tada, T., Kumada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18037 · Cited by 19
“…with HCC was determined through discussions held by the cancer board at each institution, which followed the Japanese practice guidelines for HCC. 12,13 There are no regional differences in the treatment strategy for HCC in Japan, as there are Japan Society of Hepatology specialists throughout…”
BackgroundMethodSelf-citationHepatic Resection for Hepatocellular Carcinoma
Tabrizian, P., Pero, A., & Schwartz, M. (2024) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.08.008 · Cited by 20
Aoki, T., Kudo, M., Nishida, N., Ueshima, K., Tsuchiya, K., Tada, T., Morita, M., Chishina, H., Takita, M., Hagiwara, S., et al. (2025) · Journal of Gastroenterology · doi:10.1007/s00535-025-02233-z · Cited by 21
“However, in recent years, the concepts of TACE failure/refractoriness [6, 7] or unsuitability [8] have been reported, leading to a transition in treatment strategies favoring upfront systemic therapy followed by TACE in patients with preserved liver function and a high tumor burden [9–13].”
Self-citationSugimoto, K., Saito, K., Shirota, N., Kamiyama, N., Sakamaki, K., Takahashi, H., Wada, T., Kakegawa, T., Tomita, Y., Abe, M., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13793 · Cited by 16
“Hepatocellular carcinoma (HCC) is the only type of cancer diagnosed noninvasively in high‐risk patients based on typical imaging features of CT, MRI, or contrast‐enhanced ultrasound (CEUS) often without biopsy.(1,2) Because many methods of imaging diagnostic criteria have been proposed, this may lead to some confusion…”
BackgroundOutcomes of LI-RADS US-2 Subthreshold Observations Detected on Surveillance Ultrasound
Tse, J. R., Shen, L., Bird, K. N., Yoon, L. S., & Kamaya, A. (2022) · American Journal of Roentgenology · doi:10.2214/ajr.22.27812 · Cited by 16
Tamaki, N., Tada, T., Kurosaki, M., Yasui, Y., Ochi, H., Mashiba, T., Sakamoto, A., Marusawa, H., Narita, R., Uchida, Y., et al. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01303-w · Cited by 16
“Defining the AFP response is also an important issue, especially since Atez/Bev therapy is recommended by guidelines as a first-line treatment [38, 39].”
BackgroundSelf-citationTaouli, B. A., Ba‐Ssalamah, A., Chapiro, J., Chhatwal, J., Fowler, K. J., Kang, T. W., Knobloch, G., Koh, D., Kudo, M., Lee, J. M., et al. (2023) · European Radiology · doi:10.1007/s00330-023-09928-y · Cited by 16
“…or gadoxetic acid– enhanced MRI [1] • KLCA-NCC: multiphase CT, or multiphase MRI using ECCM-MRI, or gadoxetic acid–enhanced MRI [2] • JSH: gadoxetic acid–enhanced MRI or dynamic CT [3] • CNLC: dynamic CT, or dynamic MRI using ECCM, or gadoxetic acid–enhanced MRI, or contrast-enhanced US [4, 5].”
BackgroundMethodInfluentialSelf-citationDai, H., Xiao, Y., Fu, C., Grimm, R., von Busch, H., Stieltjes, B., Choi, M. H., Xu, Z., Chabin, G., Yang, C., et al. (2024) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29404 · Cited by 20
“24 25 – 27 It is worth mentioning that in our study, HCC accounted for the vast majority of malignant tumors 10 mm according to the histopathology.”
Jiang, H., Zuo, M., Li, W., Zhuo, S., Wu, P., & An, C. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001752 · Cited by 20
“…of the prognostic nomograms were compared with major clinical staging systems including the BCLC [34] , American Joint Committee on Cancer (AJCC) [28] , China Liver Cancer (CNLC) [4] , Japan Society of Hepatology (JSH) [35] , and Hong Kong Liver Cancer (HKLC) systems [36] using Z test [37] .”
MethodState of the art and perspectives in liver transplantation
Xu, X. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.12.001 · Cited by 17
Clinical impact of carbon‐ion radiotherapy on hepatocellular carcinoma with Child‐Pugh B cirrhosis
Hiroshima, Y., Wakatsuki, M., Kaneko, T., Makishima, H., Okada, N. N., Yasuda, S., Ishikawa, H., & Tsuji, H. (2023) · Cancer Medicine · doi:10.1002/cam4.6046 · Cited by 16
Ding, Y., Wang, S., Qiu, Z., Zhu, C., Wang, Y., Zhao, S., Qiu, W., Wang, K., Lv, J., & Qi, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1284937 · Cited by 17
“Hence, integrating local therapy and systemic therapy is progressively gaining acceptance (7 – 11).”
BackgroundSurvival Improvements in Advanced Hepatocellular Carcinoma with Sequential Therapy by Era
Nakamura, Y., Hirooka, M., Hiraoka, A., Koizumi, Y., Yano, R., Morita, M., Okazaki, Y., Imai, Y., Ohama, H., Hirooka, K., et al. (2023) · Cancers · doi:10.3390/cancers15215298 · Cited by 18
“The use of three or more lines of therapy is one of the most predictive factors associated with better OS, and sequential treatment post-progression is valuable to prolong survival.”
BackgroundSelf-citationCryogenic Media in Biomedical Applications: Current Advances, Challenges, and Future Perspectives
Mokbel, K., Kodresko, A., Ghazal, H. S., Mokbel, R., TREMBLEY, J., & Jouhara, H. (2023) · In Vivo · doi:10.21873/invivo.13407 · Cited by 17
Chen, S., Shuangyan, T., Shi, F., Cai, H., Wu, Z., Wang, L., Ma, P., Zhou, Y.-M., Mai, Q., Wang, F., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1430571 · Cited by 25
Kudo, M. (2022) · Liver Cancer · doi:10.1159/000527404 · Cited by 21
Self-citationLima, H. A., Alaimo, L., Brown, Z. J., Endo, Y., Moazzam, Z., Tsilimigras, D. I., Shaikh, C. F., Resende, V., Guglielmi, A., Ratti, F., et al. (2022) · HPB · doi:10.1016/j.hpb.2022.11.008 · Cited by 14
Yin, L. W., Song, X., Guan, Y., Lan, R., Huang, Z., Li, S., & Zhang, L. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16088 · Cited by 17
Yamauchi, R., Ito, T., Yoshio, S., Yamamoto, T., Mizuno, K., Ishigami, M., Kawashima, H., Yasuda, S., Shimose, S., Iwamoto, H., et al. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-01985-w · Cited by 20
“The treatment strategy for HCC in this study was based on the guideline from Japan Society of Hepatology [11].”
MethodSelf-citationKang, J. H., Kim, N. H., Kim, D. H., Choi, Y., & Choi, J. (2023) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2023.07.008 · Cited by 18
Akahoshi, K., Shindoh, J., Tanabe, M., Watanabe, S., Takamizawa, H., Eguchi, S., Endo, I., Kubo, S., Taketomi, A., Nagano, H., et al. (2023) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.1408 · Cited by 14
Self-citationAdjuvant Therapy for Hepatocellular Carcinoma After Curative Treatment: Several Unanswered Questions
Li, L., Li, Z., Pan, L.-X., Su, J., Huang, S., Ma, L., & Zhong, J. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00030 · Cited by 20
“2,3,17 Therefore, only patients at high risk of recurrence receive adjuvant therapy.”
BackgroundSu, J., Liu, S., Xu, X.-L., Ou, J., Ye, P.-H., Zhao, B.-T., Chen, J.-S., Luo, Q.-M., Liu, J., Tang, F.-M., et al. (2024) · Liver Cancer · doi:10.1159/000542954 · Cited by 19
Kudo, M. (2023) · Liver Cancer · doi:10.1159/000533493 · Cited by 19
“The Japan Society of Hepatology published a consensus statement [14] following the APPLE consensus de fi nition of TACE-unsuitable conditions.”
BackgroundSelf-citationImai, K., Takai, K., Unome, S., Miwa, T., Hanai, T., Suetsugu, A., & Shimizu, M. (2023) · Cancers · doi:10.3390/cancers15174223 · Cited by 14
Cheung, T. T., Yu, S. C. H., Chan, S. L., Poon, R. T. P., Kwok, P. C. H., Lee, A., Tai, A., Tam, D., Cheung, C., Lai, T.-W., et al. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-405 · Cited by 13
Hu, Y., Pan, T., Cai, X., He, Q.-S., Zheng, Y., Huang, M., Jiang, Z., Chen, J., & Wu, C. T. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-486 · Cited by 14
Huang, P., Wu, F., Hou, K., Zhou, C., Xiao, Y., Wang, C., Miao, G., Yang, C., & Zeng, M. (2023) · European Radiology · doi:10.1007/s00330-023-10214-0 · Cited by 17
“Only a few guidelines allow a definitive diagnosis of subcentimeter HCC [4, 10].”
Cheng, J., Li, X., Wang, L., Chen, F., Li, Y., Zuo, G., Pei, M., Zhang, H., Yu, L., Liu, C., et al. (2023) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29052 · Cited by 13
Li, Y., Liu, W., Chen, J., Chen, Y., Guo, J., Pang, H., Zhang, W., An, C., & Li, C. (2024) · Cancer Medicine · doi:10.1002/cam4.6836 · Cited by 15
“12 It is noteworthy that advanced HCC patients are more commonly present with poor hepatic function.”
BackgroundCurrent Trends and Advancements in the Management of Hepatocellular Carcinoma
Teufel, A., Kudo, M., Qian, Y., Daza, J., Rodriguez, I., Reissfelder, C., Ridruejo, E., & Ebert, M. P. (2024) · Digestive Diseases · doi:10.1159/000538815 · Cited by 17
“In addition to AFP, measurement of PIVKA-II and AFP-L3 must play a very important role as revealed in Japan [103, 108, 109].”
Self-citationThe assessment of impaired liver function and prognosis in hepatocellular carcinoma
Pantea, R., Bednarsch, J., Schmitz, S. M., Meister, P., Heise, D., Ulmer, T. F., Neumann, U. P., & Lang, S. A. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2442573 · Cited by 17
Liver-Directed Treatment Options Following Liver Tumor Recurrence: A Review of the Literature
Aquina, C. T., Eskander, M. F., & Pawlik, T. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.832405 · Cited by 13
“While there are no published algorithms regarding liver function, tumor stage, and first-line treatment recommendations for recurrent HCC, the Barcelona Clinic Liver Cancer and Japan Society of Hepatology treatment strategy algorithms can be extrapolated and utilized as treatment guides (64, 65).”
BackgroundSurveillance for hepatocellular carcinoma: current status and future perspectives for improvement
Stefanini, B., Tonnini, M., Serio, I., Renzulli, M., & Tovoli, F. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2052276 · Cited by 13
“As a notable exception, the Japanese Society of Hepatology (JSH) recommends Gd-EOB-DTPA-MRI for patients with elevated serum markers of HCC but with negative US examination [77].”
BackgroundHatanaka, T., Kakizaki, S., Hiraoka, A., Kariyama, K., Tsuji, K., Ishikawa, T., Toyoda, H., Yasuda, S., Naganuma, A., Tada, T., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4850 · Cited by 14
Self-citationKim, T. H., Kim, B. H., Park, J., Cho, Y. R., Koh, Y. H., Chun, J. W., Oh, E. S., Lee, D. Y., Lee, S. U., Suh, Y., et al. (2022) · Cancers · doi:10.3390/cancers14184445 · Cited by 13
Advances in Immunotherapy for Hepatocellular Carcinoma
Hagiwara, S., Nishida, N., & Kudo, M. (2023) · Cancers · doi:10.3390/cancers15072070 · Cited by 18
“In addition to high tumor burden, TACE-unsuitable patients include poorly differentiated HCC, multinodular HCC, and diffuse HCC [55,56].”
BackgroundSelf-citationKinami, T., Amioka, K., Kawaoka, T., Uchikawa, S., Yamasaki, S., Kosaka, M., Johira, Y., Yano, S., Naruto, K., Ando, Y., et al. (2023) · Cancers · doi:10.3390/cancers15082304 · Cited by 15
Chen, S., Yuan, B., Yu, W., Wang, X., He, C., & Chen, C. (2022) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-022-05421-x · Cited by 13
Peng, W. J., Zhang, X., Li, C., Zhu, X., Li, Q., Chen, W., Lu, W., Liu, C., Zhou, Y., Shi, Y., et al. (2022) · British journal of surgery · doi:10.1093/bjs/znac334 · Cited by 12
Vogel, A., Ochsenreither, S., Zager, J. S., Wacker, F. K., & Saborowski, A. L. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102501 · Cited by 12
Quek, J., Tan, D. J. H., Chan, K. E., Lim, W. H., Ng, C. H., Ren, Y. P., Koh, T. K., Teh, R., Xiao, J., Fu, C. E., et al. (2023) · Digestive Diseases · doi:10.1159/000531016 · Cited by 15
Tada, T., Kumada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., et al. (2023) · Liver International · doi:10.1111/liv.15753 · Cited by 15
Self-citationHepatocellular Carcinoma—Southeast Asia Updates
Singh, S. P., Arora, V., Madke, T., & Sarin, S. K. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000684 · Cited by 11
“α-Fetoprotein is the blood test that can be used for surveillance, with an AFP value of ≥20 ng/mL detecting HCC at a sensitivity of 40% to 60% and specificity of 80%.(25) Protein induced by vitamin K absence-II can also be used as a tumor marker in Asian countries.”
BackgroundToshida, K., Itoh, S., Yoshiya, S., Nagao, Y., Tomino, T., Izumi, T., Iseda, N., Toshima, T., Ninomiya, M., & Yoshizumi, T. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16441 · Cited by 13
Ohama, H., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Hatanaka, T., Tani, J., Takaguchi, K., Atsukawa, M., Itobayashi, E., et al. (2024) · Cancer Reports · doi:10.1002/cnr2.2042 · Cited by 13
“A diagnosis of HCC was based on the consensus statement of the Japan Society of Hepatology 18 and tumor staging on BCLC stage.”
MethodSelf-citationHepatocellular carcinoma systemic treatment update: From early to advanced stage
Teng, W., Wu, T.-C., & Lin, S. (2024) · Biomedical Journal · doi:10.1016/j.bj.2024.100815 · Cited by 17
Wang, F., Yu, J., Lu, X., Numata, K., Ruan, L., Zhang, D., Liu, X., Li, X., Wan, M., Zhang, W., et al. (2025) · Abdominal Radiology · doi:10.1007/s00261-025-04825-y · Cited by 13
Kodama, Y., Ueshima, K., Moriguchi, M., Inaba, Y., Yamashita, T., Iwamoto, H., Ueno, M., Ogasawara, S., Kuzuya, T., Kodama, T., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13648-5 · Cited by 25
“…is recommended as a first-line treatment for patients with unresectable HCC (uHCC) in the Japanese guidelines for liver cancer treatment from the Japan Society of Hepatology [5, 6], as well as the guidelines of the BCLC group [4] and the American Association for the Study of Liver Diseases [7].”
Self-citationKim, N. J., Li, M., Vutien, P., Mecham, B., Borgerding, J. A., Swarts, K., Atuluru, P., Michel, M., Giustini, A. B., Mezzacappa, C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.08.021 · Cited by 18
Iwamoto, H., Niizeki, T., Nagamatsu, H., Ueshima, K., Tani, J., Kuzuya, T., Kasai, K., Kooka, Y., Hiraoka, A., Sugimoto, R., et al. (2022) · Cancers · doi:10.3390/cancers14194873 · Cited by 12
“Nowadays, systemic treatment has been remarkably developed for hepatocellular carcinoma (HCC) [1].”
BackgroundSelf-citationSugimoto, R., Satoh, T., Ueda, A., Senju, T., Tanaka, Y., Yamashita, S., Koyanagi, T., Kurashige, T., Higuchi, N., Nakamura, T., et al. (2022) · Medicine · doi:10.1097/md.0000000000030871 · Cited by 12
“Tumor-node-metastasis staging of liver cancer by the Liver Cancer Study Group of Japan (6th edition)[11] was used to evaluate tumor progression in parallel with Barcelona Clinic Liver Cancer (BCLC) staging.”
MethodKamiyama, N., Sugimoto, K., Nakahara, R., Kakegawa, T., & Itoi, T. (2023) · Journal of Medical Ultrasonics · doi:10.1007/s10396-023-01390-z · Cited by 12
Yang, C., Yang, H., Luo, Y., Li, F., Cong, T., Li, Y., Ye, F., & Li, X. (2024) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-024-03730-z · Cited by 12
“[1, 5].”
Lv, X., Zhang, P., Zhang, E., & Yang, S. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03765-7 · Cited by 11
Xiong, Y., Ouyang, Y., Fang, K., Sun, G., Tu, S., Xin, W., Wei, Y., & Xiao, W. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/4558782 · Cited by 11
“Hepatectomy, liver transplantation, thermal ablation, transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), targeted therapy, and immunotherapy are currently the most common treatments for HCC [3, 4].”
BackgroundRetractedShigematsu, Y., Tanaka, K., Amori, G., Kanda, H., Takahashi, Y., Takazawa, Y., Takeuchi, K., & Inamura, K. (2023) · Hepatology Research · doi:10.1111/hepr.13988 · Cited by 11
“21 The presence of the VETC pattern in ≥ 1% of the tumor area, as defined originally, 14 was used to designate tumors as VETC ‐ positive.”
MethodHuang, C., Xiao, X., Zhou, L., Chen, F., Wang, J., Hu, X., & Gao, C. (2023) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24990 · Cited by 15
Patlak Reconstruction Using Dynamic 18F-FDG PET Imaging for Evaluation of Malignant Liver Tumors
Kaneko, K., Nagao, M., Yamamoto, A., Yano, K., Honda, G., Tokushige, K., & Sakai, S. (2023) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005013 · Cited by 11
Metadata
- Authors
- Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., Izumi, N., Moriguchi, M., Ogasawara, S., Minami, Y., Ueshima, K., Murakami, T., Miyayama, S., Nakashima, O., Yano, H., Sakamoto, M., Hatano, E., Shimada, M., Kokudo, N., Mochida, S., Takehara, T., & HCC Expert Panel of the Japan Society of Hepatology
- Affiliations
- Kindai University Hospital (JP)
- Toranomon Hospital (JP)
- The University of Tokyo (JP)
- Okayama City Hospital (JP)
- Juntendo University (JP)
- Ogaki Municipal Hospital (JP)
- Ikeda Municipal Hospital (JP)
- Ehime Prefectural Central Hospital (JP)
- National Cancer Center Hospital East (JP)
- Musashino Red Cross Hospital (JP)
- Kyoto Prefectural University of Medicine (JP)
- Chiba University (JP)
- Kobe University (JP)
- Fukui-ken Saiseikai Hospital (JP)
- Kurume University (JP)
- Keio University (JP)
- Hyogo Medical University (JP)
- Tokushima University (JP)
- National Center for Global Health and Medicine (JP)
- Saitama Medical University (JP)
- The University of Osaka (JP)
- ORCID
- Kudo, Masatoshi
- Kawamura, Yusuke
- Hasegawa, Kiyoshi
- Tateishi, Ryosuke
- Kariyama, Kazuya
- Shiina, Shuichiro
- Toyoda, Hidenori
- Hiraoka, Atsushi
- Ikeda, Masafumi
- Izumi, Namiki
- Moriguchi, Michihisa
- Ogasawara, Sadahisa
- Minami, Yasunori
- Ueshima, Kazuomi
- Murakami, Takamichi
- Miyayama, Shiro
- Nakashima, Osamu
- Yano, Hirohisa
- Sakamoto, Michiie
- Hatano, Etsuro
- Shimada, Mitsuo
- Kokudo, Norihiro
- Mochida, Satoshi
- Takehara, Tetsuo
- Venue
- Liver Cancer
- Publisher
- S. Karger AG
- Published
- 2021
- Volume
- 10
- Issue
- 3
- Pages
- 181-223
- ISSN
- 1664-5553 (ISSN-L)
- 2235-1795
- PMC
- PMC8237791
- OpenAlex
- W3162270595
- Cited by
- 678
- References
- 200
- Citations by year
- 2026: 78 · 2025: 137 · 2024: 158 · 2023: 177 · 2022: 108 · 2021: 17
- FWCI
- 14.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Liver Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc)
- Funders
- Japan Society for the Promotion of Science (19K08199)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, consensus statement, clinical guidelines, HCC diagnosis, HCC treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.